Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-18
2006-04-18
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S326000, C514S343000, C514S423000, C544S141000, C544S372000, C546S208000, C546S278400, C548S537000
Reexamination Certificate
active
07030114
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4069318 (1978-01-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4071621 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4074057 (1978-02-01), Kawamatsu et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4097591 (1978-06-01), Okamoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4804676 (1989-02-01), Inaoka et al.
patent: 4910190 (1990-03-01), Bergeson et al.
patent: 4977168 (1990-12-01), Bernat et al.
patent: 4981873 (1991-01-01), Witte et al.
patent: 5338755 (1994-08-01), Wagnon et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5397801 (1995-03-01), Wagnon et al.
patent: 5481005 (1996-01-01), Wagnon et al.
patent: 5578633 (1996-11-01), Wagnon et al.
patent: 5650428 (1997-07-01), Ohmori et al.
patent: 5686628 (1997-11-01), Veale et al.
patent: 6221888 (2001-04-01), Durette et al.
patent: 6291511 (2001-09-01), Durette et al.
patent: 6147073 (1975-04-01), None
patent: 2357334 (1974-06-01), None
patent: 2655636 (1977-06-01), None
patent: 0526348 (1993-02-01), None
patent: 9711143.9 (1997-05-01), None
patent: 9714314.3 (1997-07-01), None
patent: 9714316.8 (1997-07-01), None
patent: 9714335.8 (1997-07-01), None
patent: 9722674.0 (1997-10-01), None
patent: 9800680.2 (1998-01-01), None
patent: 9800684.4 (1998-01-01), None
patent: 9800686.9 (1998-01-01), None
patent: 01454732 (1992-05-01), None
patent: 04154732 (1992-05-01), None
patent: 6-16625 (1994-01-01), None
patent: 08073422 (1996-03-01), None
patent: WO 92/16459 (1992-10-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 94/07815 (1994-04-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 96/20725 (1996-07-01), None
patent: WO 96/20949 (1996-07-01), None
patent: WO 96/22966 (1996-08-01), None
patent: 97/03094 (1997-01-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 98/04247 (1998-02-01), None
patent: WO 98/42656 (1998-10-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 98/53818 (1998-12-01), None
patent: WO 98/54207 (1998-12-01), None
patent: WO 98/58902 (1998-12-01), None
patent: 99/06436 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
Gamo, Chemical Abstract 117:211689, 1992.
V. Simanis et al.,Int. J. Pept. Protein Res.(1982), 19(1), 67-70.
D. Leibfritz et al.,Tetrahedron(1982),38(14), 2165-81.
A.M. El-Nagger et al.,Acta. Pharm. Jugosl.(1985), 35(1), 15-22.
Chemical Abstract No. 126040, vol. 74, No. 23 (Jun. 7, 1971).
Chemical Abstract No. 176262, vol. 99, No. 21 (Nov. 21, 1983)
Chemical Abstract No. 210288, vol. 106, No. 25 (Jun. 22, 1987).
Chemical Abstract No. 167952, vol. 108, No. 19 (May 9, 1988).
Chemical Abstract No.34164, vol. 125, No. 3 (Jul. 15, 1996).
Engleman, V.W., et al. “Cell Adhesion Integrins as Pharmaceutical Targets.”Ann. Reports in Med. Chem.31: 191-200 (1996).
Hauptmann, J., et al. “Degredation of a Benzamidine-Type Synthetic Inhibitor of Coagulation Enzymes in Plasma of Various Species.”Thrombosis Research.61: 279-284 (1991).
Leibfritz, D., et al., “Synthese Von 2-Methylalanin-Peptiden, Die pH-Abhangigkeit Ihrer 13C-NMR-Spektren Und Eine Neue Methode Zur Auswetung Uber CS-Diagramme.”Tetrahedron.18(14): 2165-2181 (1982). (Translation enclosed).
Voigt, B., et al, “Synthese von Nα-(Arylsulfonyl-L-prolyl)-und Nα-Benzyloxycarbonl-L-prolyl)-D,L-4-amidinophenyl-alaninamiden als Throbininhibitoren.”Pharmazie. 41: 233-235 (1986).
Baudy Reinhardt Bernhard
Dressen Darren B.
Grant Francine S.
Konradi Andrei W.
Pleiss Michael A.
Elan Pharmaceuticals Inc.
Rao Deepak
Wyeth
LandOfFree
Compounds which inhibit leukocyte adhesion mediated by VLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds which inhibit leukocyte adhesion mediated by VLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds which inhibit leukocyte adhesion mediated by VLA-4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594578